The PRI is the only expert in Europe equipped to help its members in their development of medicinal probiotics, part of the new and rapidly expanding Microbiota & Human Health industry.
The human microbiota plays a central role in human health; it therefore opens a door to a new type of medicine, one which is preventive and personalized. Pharmabiotics™ are an essential means in acting on the microbiota.
Medicinal probiotics, or pharmabiotics™, therefore represent a more effective method of treating several pathologies by healthcare providers, as well as a new growth opportunity for companies.
And yet the Microbiota & Human Health industry is still developing and will need publicity and structure. Moreover, the regulatory documentation for medicinal products was designed for chemical molecules and will require adaptation for the specific nature of probiotics (living microorganisms). The PRI is the only expert in Europe which can help its members negotiate this difficult regulatory situation.
Today we are on the brink of seeing Europe’s first drug marketing authorisations for medicinal probiotics. Are there opportunities for your business in this developing market space?